TMEM106B and infection: Combined, these two substitutions abrogated S1 binding in vitro (Figure S3F) and the ability of TMEM106B to support infection with SARS-CoV-2 Belgium/GHB-03021/2020 (Figure 3E) and VOC omicron (Figure 3F), without affecting correct TMEM106B expression and localization (Figure S3G).